The role of indole-induced immune dysregulation in collagen-inducedarthritis

吲哚诱导的免疫失调在胶原诱导的关节炎中的作用

基本信息

  • 批准号:
    10605039
  • 负责人:
  • 金额:
    $ 3.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-12-01 至 2025-11-30
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Pre-clinical Rheumatoid Arthritis (RA) is a period in which systemic autoimmunity develops in the years prior to onset of clinically apparent disease. Here, we aim to define the mechanisms leading to pre-clinical autoimmunity, which could inform the design of therapies to block these pathways and prevent RA. Our group has been integral in identifying and investigating the “mucosal origins” hypothesis of RA, utilizing the collagen-induced arthritis (CIA) model to demonstrate the requirement of the microbiome for disease development. We recently identified a bacterial-derived tryptophan metabolite, indole, as a key regulator of autoimmunity in this model. Depletion of either the microbiome (using broad-spectrum antibiotics) or dietary tryptophan is protective against CIA, and supplementation with indole in either setting reverses this protection. This indole-CIA model provides, for the first time, a model in which a single bacterial metabolite is sufficient for disease development. Based on our preliminary findings that Th17 cells and inflammatory cytokine production (especially IL-6) are elevated in this indole-CIA model, I hypothesize that indole is a bioactive metabolite that promotes CIA by skewing Th17 cell differentiation and stimulating antigen presenting cells (APCs) to produce IL-6. The experiments outlined in this proposal are designed to define the effects of indole on CIA. Aim 1 will determine the effect of indole on CD4 effector T cell responses, both in the indole-CIA model and in a model of antigen-specific T cell responses utilizing OT-II transgenic mice. Aim 2 will then identify the source of and requirement for indole-mediated IL-6 production. I will utilize combined single cell RNA/ATACseq to identify the cell subsets and signaling pathways in which indole induces IL-6 production. Finally, I will test the requirement for dendritic cell (DC)-mediated IL-6 production in indole-CIA. Successful completion of these aims will (1) define the cell subsets and functions affected by indole in the indole-CIA model, which will allow for future mechanistic studies to better define and modulate this process, (2) define the role of DC-derived IL-6 in CIA, which has never been shown, and (3) generate hypotheses to later identify the signaling pathways affected by indole stimulation, which will be necessary to understand the mechanisms by which indole incites autoimmunity. Altogether, these findings will fill a critical knowledge gap regarding the role of the microbiome in the development of inflammatory arthritis. Furthermore, through these studies I will become an expert in mucosal immunology, learn to design and test rigorous hypotheses, and become proficient in cutting-edge bioinformatic techniques through analysis of the RNA/ATACseq data generated in Aim 2. The training gained through this proposal will enable me to be well- positioned for a research fellowship in rheumatology and apply skills needed for a successful K08 in the future.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brenda J Seymour其他文献

Brenda J Seymour的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 3.58万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 3.58万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 3.58万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 3.58万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 3.58万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 3.58万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 3.58万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 3.58万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 3.58万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 3.58万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了